Results 21 to 30 of about 152,115 (284)

A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers

Разработка и регистрация лекарственных средств, 2019
Introduction. Bevacizumab is a monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab is used as a targeted monoor combination therapy for different solid tumors.
M. A. Kolganova, N. S. Bagaeva, Yu. V. Medvedev, I. E. Shohin, A. V. Demchinskaya, T. N. Palkina, D. A. Salazanov, G. E. Konopleva, M. S. Sheremeteva, Sh. Z. Archuadze, Ya. V. Lavrovsky, A. Yu. Savchenko, M. Yu. Samsonov   +12 more
doaj   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Metformin alleviates bevacizumab-induced vascular endothelial injury in mice through growth differentiation factor 15 upregulation [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Bevacizumab is a commonly used anticancer drug in clinical practice, but it often leads to adverse reactions such as vascular endothelial damage, hypertension, arterial and venous thrombosis, and bleeding.
Liqiang Chen, Yajuan Yin, Chunmiao Liu, Junying Liu, Mingqi Zheng, Yida Tang, Qing Yang, Jing Liu, Fan Chen, Lanbo Liu, Gang Liu   +10 more
doaj   +1 more source

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces

MDM Policy & Practice, 2021
Background. Real-world evidence can be a valuable tool when clinical trial data are incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic colorectal cancer (mCRC) based on significant survival improvements in initial ...
Reka E. Pataky, Jaclyn Beca, David Tran, Wei Fang Dai, Erind Dvorani, Wanrudee Isaranuwatchai, Stuart Peacock, Riaz Alvi, Winson Y. Cheung, Craig C. Earle, Scott Gavura, Kelvin K. W. Chan   +11 more
doaj   +1 more source

Regulatory withdrawal of medicines marketed with uncertain benefits : the bevacizumab case study [PDF]

, 2015
Acknowledgements Professor Elizabeth Roughead is funded by a Future Fellowship from the Australian Research Council. The views expressed are those of the authors, the sponsor had no role in the preparation of the manuscript.Peer reviewedPublisher ...
Entwistle, Vikki, Nguyen, Tuan, Roughead, Elizabeth, Vitry, Agnes   +3 more
core   +1 more source

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients. Meta-regression analysis of randomized trials [PDF]

, 2011
Background: Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile.
Cuppone F., Bria E., Vaccaro V., Puglisi F., Fabi A., Sperduti I., Carlini P., Milella M., Nistico C., Russillo M., Papaldo P., Ferretti G., Aapro M., Giannarelli D., Cognetti F.   +14 more
core   +3 more sources

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial [PDF]

, 2014
Background: Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data are lacking regarding their natural history, associated complications and infusion pump performance in patients with ...
A Surov, AA Martoni, C Araújo, C Twelves, D Fagnani, D Haller, DC McGee, DZ Xiang, E Chu, E Chu, E McKenna, E Van Cutsem, EA Poplin, EB Lamont, F Ng, G Perrocheau, H-J Schmoll, I Kriegel, J Cassidy, J Cassidy, J Kawamura, J Shen-Gunther, L Cavanna, L Garrison, LB Saltz, M Gann Jr, M Karthaus, M Verso, M W Saif, MM Beckers, N Barbetakis, N Starling, P Debourdeau, R Biffi, S Lee, T Cartwright, T Conroy, The Meta-Analysis Group In Cancer, W Saber, W Scheithauer, W Sun, Y Inaba   +41 more
core   +2 more sources

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma

Cancer Medicine, 2020
Introduction Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose‐schedule are debated. A lower dose‐schedule than standard‐dose bevacizumab (10 mg/kg 2‐weekly) might offer similar benefits with lower costs.
Jack Patrick Gleeson, Fergus Keane, Niamh M. Keegan, Emin Mammadov, Emily Harrold, Abdullah Alhusaini, Jeffrey Harte, Austin Eakin‐Love, Philip J. O'Halloran, Stephen MacNally, Bryan T. Hennessy, Oscar S. Breathnach, Liam Grogan, Patrick G. Morris   +13 more
doaj   +1 more source